OncoMatch/Clinical Trials/NCT06768905
IOMAB-CAR-T Followed by CAR-T Cell Therapy in R/R DLBCL
Is NCT06768905 recruiting? Yes, currently enrolling (Sep 2026). This Phase 1/2 trial studies multiple treatments including Iomab-B and CAR-T cell for non hodgkin lymphoma.
Treatment: Iomab-B · CAR-T cell — This study is being done to determine the safety, efficacy and tolerability of a single 50 mCi dose of 131I-Apamistamab given prior to FDA approved (commercially available) infusion in patients with Relapsed or refractory (R/R) non-Hodgkin lymphoma.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Non-Hodgkin Lymphoma
Diffuse Large B-Cell Lymphoma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: chemoimmunotherapy
relapsed or refractory DLBCL or high-grade B-cell lymphoma (HGBL) following at least one or more prior chemoimmunotherapy regimen (with at least one course including an anthracycline and CD20-directed therapy)
Cannot have received: radiopharmaceuticals for lymphoma treatment indication
Patients with prior history of treatment with radiopharmaceuticals for lymphoma treatment indication
Lab requirements
Blood counts
ANC ≥1.0k/µL, platelets ≥50k/µL, hemoglobin ≥8g/dL (without blood product or G-CSF support in prior 7 days)
Kidney function
Creatinine clearance ≥50 mL/min (Cockroft-Gault)
Liver function
Total bilirubin ≤1.5x ULN, AST and ALT ≤3x ULN (≤5x ULN if liver dysfunction due to malignancy or Gilbert's disease, direct bilirubin ≤3.0 mg/dL)
Cardiac function
LVEF ≥40% by echocardiogram or MUGA; QTcF ≤470mSec on EKG
Creatinine clearance ≥50 mL/min as calculated by the Cockroft-Gault formula. Total bilirubin ≤1.5x ULN, AST and ALT ≤3x ULN, unless liver dysfunction is thought to be related to underlying malignancy or secondary to Gilbert's disease in which case the direct bilirubin should be ≤3.0 mg/dL, and AST and ALT ≤5x ULN. Absolute neutrophil count ≥1.0k/µL, Platelets ≥50k/µL, Hemoglobin ≥8g/dL. LVEF ≥40% by echocardiogram or MUGA; QTcF ≤470mSec on EKG.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of Texas Southwestern Medical Center · Dallas, Texas
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06768905 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior radiopharmaceuticals for lymphoma treatment indication disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify